Clinical Trial Update: Efficacy and Safety of AG10 in Subjects with Transthyretin Amyloid Polyneurophathy [Phase 3]

View source ↗

Summary

A Phase 3 study of AG10 for Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathy has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Transthyretin-related Familial Amyloid Polyneuropathy

Drugs mentioned

• AG10

Snippet

Sponsor: Eidos Therapeutics, a BridgeBio company | Conditions: Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathy | Phase 3 | Status: WITHDRAWN